Galectin Therapeutics/$GALT
1D1W1MYTD1Y5YMAX
Capital at risk
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
- Ticker
- $GALT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 9
- Headquarters
- Norcross, United States
- Website
- galectintherapeutics.com
GALT Metrics
BasicAdvanced
$392M
-
-$0.43
0.39
-
Price and volume
Market cap
$392M
Beta
0.39
52-week high
$7.13
52-week low
$2.03
Average daily volume
348K
Financial strength
Current ratio
0.097
Quick ratio
0.088
Long term debt to equity
-0
Total debt to equity
-1.052
Interest coverage (TTM)
-2.02%
Profitability
Management effectiveness
Return on assets (TTM)
-64.18%
Return on equity (TTM)
21.92%
Valuation
Price to book
-1.86
Price to tangible book (TTM)
-1.86
Price to free cash flow (TTM)
-15.951
Free cash flow yield (TTM)
-6.27%
Free cash flow per share (TTM)
-0.244
Growth
Earnings per share change (TTM)
-33.10%
3-year earnings per share growth (CAGR)
-13.93%
10-year earnings per share growth (CAGR)
-7.01%
What the Analysts think about GALT
Analyst ratings (Buy, Hold, Sell) for Galectin Therapeutics stock.
Analyst projections of the future price of Galectin Therapeutics stock.
Bulls say / Bears say
The FDA agreed with Galectin on the planned Phase 3 primary endpoint, central endoscopy methodology, single 2 mg/kg dose, and a regulatory path toward potential full approval, materially reducing near-term regulatory uncertainty. (SEC)
NAVIGATE produced encouraging efficacy signals: the 2 mg/kg dose reduced varices by 49.3% in the predefined per-protocol population and by 68.1% in the U.S. subgroup, while adverse-event and serious-adverse-event rates were comparable with placebo. (SEC)
The August 2026 debt-to-equity transaction eliminated approximately $105.8 million of debt and accrued interest, while an undrawn $10 million credit facility remained available, substantially improving balance-sheet flexibility for advancing belapectin. (SEC)
NAVIGATE’s 2 mg/kg arm reduced varices by 43.2% in the intent-to-treat population, but the composite endpoint did not reach statistical significance, leaving the pivotal efficacy case reliant on per-protocol and subgroup results. (SEC)
The July 2026 debt conversion removed approximately $105.8 million of obligations but required issuing 34.4 million shares; shares outstanding subsequently rose to 100.85 million, creating substantial dilution for existing holders. (SEC)
Galectin remains pre-revenue and loss-making, reporting a $9.2 million Q2 2026 net loss and $13.3 million of cash; its filing says continued operations depend on additional financing after June 2027 and warns that funding may not be available on favorable terms. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
GALT Financial Performance
Revenues and expenses
GALT Earnings Performance
Company profitability
Upcoming events
No upcoming events
GALT News
AllArticlesVideos
Funds containing GALT
Fund name | Fund size | $GALT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.